VA Boston Healthcare System
Boston, Massachusetts, 02130, United States
NCT Number: NCT03380819
The VetSeq Study is a pilot intervention study exploring the feasibility of integrating genome sequencing into clinical care at the VA Boston Healthcare System.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Boston, Massachusetts, 02130, United States
The VetSeq Study is a pilot intervention study exploring the feasibility of integrating genome sequencing into clinical care at the VA Boston Healthcare System. Healthcare providers may refer any patients who they think might benefit from diagnostic whole genome or exome sequencing. Providers will briefly discuss genome sequencing and the pilot study with potentially eligible patients. If a patient is interested, the provider will refer him/her to the study by contacting the study staff and providing the reason (clinical question) why the provider thinks genome sequencing might be beneficial for the patient. The study staff will meet with the patient to conduct a baseline interview and survey, obtain informed consent for sequencing, and obtain a blood specimen for sequencing. A clinical laboratory will perform exome or whole-genome sequencing and issue an interpreted genome report including any variant possibly explaining the patient's condition, in addition to secondary monogenic, carrier, and pharmacogenomic results. This report will be sent to the referring provider, who will document the results and associated decision-making in the medical record. Approximately 3 months later, study staff will conduct a follow-up interview and survey with the participating patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
Time frame: Baseline
Identification of a genetic variant that explains the patient's indication for sequencing
Time frame: Baseline
Pathogenic or likely pathogenic variants in over 4600 genes associated with monogenic disease risk, carrier status variants, and pharmacogenomic results
Time frame: 3 months
Evidence that genome sequencing results changed the medical care of the patient
Time frame: 3 months
Veterans Rand (VR)-12
VA Boston Healthcare System
Fed
Clinical Safety and Efficacy of Pharmacogenetics in Veteran Care
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06341127
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes
Toronto, Ontario, Canada
View Trial DetailsNCT05499091
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes
Angers, France
View Trial DetailsNCT04586075
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes
Madison, Wisconsin, United States
View Trial DetailsNCT06072079
Chromosome Aberrations, Chromosome Abnormality
Stockholm, Sweden
View Trial Details